Genentech Rituxan Sales Dip On Medicare Rate Cut; Demand “Still Strong”
Rituxan sales appear to have stabilized following a brief dip in January related to changes in Medicare Part B reimbursement for the oncologic, Genentech told investors April 8
Rituxan sales appear to have stabilized following a brief dip in January related to changes in Medicare Part B reimbursement for the oncologic, Genentech told investors April 8